Affimed parts with CSO
Dr. Martin Treder has informed Affimed that he intends to step down from his position as Chief Scientific Officer to pursue new opportunities.
ADVERTISEMENT
About Michael Kuhrt
This author has not written his bio yet.
But we are proud to say that Michael Kuhrt contributed 541 entries already.
Entries by Michael Kuhrt
Functional sugars made by biotech for everyone
Rare functional sugars provide huge market opportunities. European Biotechnology spoke with Stefan Jennewein, Founder and CEO of Jennewein Biotechnologies, about the company’s strategy and its latest expansions to the Chinese market.
Mark Hammond joins PBD Biotech
Novel diagnostic developer PBD Biotech announces the appointment of new CEO Mark Hammond to drive the company’s expansion.
Mogrify appoints new CBO and COO
Mogrify appoints 15 new staff including, Dr Karin Schmitt as Chief Business Officer and Joe Foster as Chief Operating Officer
Bionure appoints Dr. Lucia Septien as CMO
Bionure, a biotech company specialized in neuroprotection, today announces that it has appointed Dr. Lucia Septien as chief medical officer.
Immunocore appoints Mohammed Dar
Immunocore has appointed Dr Mohammed Dar as Head of Clinical Development and Chief Medical Officer. Mohammed Dar will lead the continued clinical development of tebentafusp(IMCgp100) and other key programmes in Immunocore’s pipeline.
Dr Stuart Quin appointed as CEO of Medica Group
Medica Group Plc (LSE:MGP) announces that Dr Stuart Quin has been appointed as Chief Executive Officer. Dr Quin will join Medica and its Board of Directors on 1 September 2019. John Graham will remain as Chief Executive Officer until Dr Quin joins the company.
Lessons from a former poster child
With partner Indivior exchanging a late-stage addiction programme for early-stage alternatives, 2019 did not start exceptionally well for Addex Therapeutics. But, the Swiss drug developer has shown the stamina to withstand far more serious setbacks in the past. For EuroBiotech, Addex’s CEO Tim Dyer recounts the company’s history and outlines its future.
Immunic appoints Tamara A. Seymour as Interim CFO
Immunic, Inc., a clinical-stage biopharmaceutical company focused on developing best-in-class, oral therapies for the treatment of chronic inflammatory and autoimmune diseases, today announced the appointment of Tamara A. Seymour, MBA, as its Interim Chief Financial Officer, effective April 26, 2019. Ms. Seymour is a corporate finance veteran with three decades of experience in the biotech and life sciences industries.
Jo Easton Appointed Non-Executive Director
Medica Group Plc (LSE:MGP) announces that Jo Easton has been appointed to the Group’s Board of Directors as a non-executive director. On joining the Board, Jo will be appointed to the audit, nomination and remuneration committees.